期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 27, 期 9, 页码 1021-1029出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2017.1344217
关键词
Mirna; cardiovascular; biomarker; diagnosis; miR-499; inhibitors
资金
- National Natural Science Foundation of China [31430041, 81230005]
- China Postdoctoral Science Foundation [2016M590616, 2017M612189]
- Doctoral foundation of Shandong province [201601016]
Introduction: A number of miRNAs have been reported to be critically involved in the regulation of cardiovascular disease (CVDs). Therefore, the development of potent analogues/inhibitors for miRNAs have thus become a key focus in the present drug discovery. In this review, we discuss the basic research and clinical use of miRNAs as the early diagnosis and therapeutic targets for CVD. We have also focused on the efficiency of therapeutically targeting miR-499, which is considered as one of the most promising molecules for treating CVDs. Areas covered: In this review, we have discussed the patents and patent applications related to miRNAs detected in CVD patients published in recent years. This review also covers the expression pattern of miR-499, as well as it highlights functions of its inhibitors in CVD. We used Google and Pubmed search engines to find relevant patents. Expert opinion: Although a massive number of miRNAs are patented as CVD biomarkers, further work is absolutely required to evaluate the reliable diagnostic values and therapeutic potential of these candidates. Overall, targeting miRNAs is definitely a promising strategy to be investigated for diagnosis and treatment of CVDs in future, however, the delivery system and off-targets effects are still a difficult challenge need to be elucidated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据